Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

RECRUITING

Identifier: CI-TRIAL-00078198
Entity page: /trial/NCT06473259 ↗
Edges: 8

Neighbours: 2 cancers6 drugs
Drawn: 8 of 8 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients condition of …CONDITION_OFderived2 of 2
← condition of	Malignant Prostate Neoplasm registry condition “Prostate Cancer” mapped CURATED_EXACT	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
← condition of	Neoplasm registry condition “Metastatic Tumor” mapped CURATED_BROADER

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients intervention of …INTERVENTION_OFderived6 of 6
← intervention of	Abirateronesmall molecule registry intervention “Abiraterone acetate tablets” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Apalutamidesmall molecule registry intervention “Apalutamide Oral Tablet” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Darolutamidesmall molecule registry intervention “Darolutamide Oral Tablet” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Docetaxelsmall molecule registry intervention “Docetaxel” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Enzalutamidesmall molecule registry intervention “Enzalutamide Oral Tablet” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Triptorelinother registry intervention “Triptorelin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients intervention of …INTERVENTION_OFderived6 of 6

← intervention of

Abirateronesmall molecule

registry intervention “Abiraterone acetate tablets” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Apalutamidesmall molecule

registry intervention “Apalutamide Oral Tablet” (DRUG) mapped ALIAS

—